CLL relapsed or refractory to fludarabine
Showing 1 - 25 of >10,000
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia Trial in Los Angeles (radiation, procedure, biological, drug)
Active, not recruiting
- Multiple Myeloma
- +4 more
- Total Body Irradiation
- +5 more
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Dec 21, 2022
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL Trial in Houston
Recruiting
- Refractory B-Cell Non-Hodgkin Lymphoma
- +4 more
- CD19.CAR-aNKT cells
- +2 more
-
Houston, Texas
- +1 more
Aug 19, 2022
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory Trial in United States
Completed
- Non-Hodgkin's Lymphoma, Relapsed
- +8 more
- PBCAR20A
- +2 more
-
Duarte, California
- +4 more
Jan 4, 2023
Acute Myeloid Leukemia Trial in United States (Cyclophosphamide, Fludarabine, KITE-222)
Recruiting
- Acute Myeloid Leukemia
- Cyclophosphamide
- +2 more
-
Stanford, California
- +6 more
Aug 10, 2022
Leukemia, Myeloid, Acute Trial in Chongqing (Fludarabine, Cytoxan, Dual CD33-CLL1 CAR-T cells)
Not yet recruiting
- Leukemia, Myeloid, Acute
- Fludarabine
- +2 more
-
Chongqing, Chongqing, ChinaDepartment of Hematology, Xinqiao Hospital
Aug 20, 2021
Chronic Lymphocytic Leukemia Trial in San Diego (ISF35)
Completed
- Chronic Lymphocytic Leukemia
- ISF35
-
San Diego, CaliforniaUniversity of California, San Diego Moores Cancer Center
Sep 15, 2021
AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)
Recruiting
- AML, Adult
- CLL1 CAR-NK cell injection
-
Hangzhou, Zhejiang, ChinaClinical research ethics committee of the first affiliated hospi
Aug 30, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma Trial in Worldwide (BMS-986403, Fludarabine, Cyclophosphamide)
Recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma
- BMS-986403
- +2 more
-
Birmingham, Alabama
- +24 more
Jul 6, 2022
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- Cyclophosphamide
- +2 more
-
São Paulo, BrazilHospital Israelita Albert Einstein
Jan 20, 2023
Relapsed/Refractory Large B Cell Lymphoma Trial (biological, drug, genetic)
Not yet recruiting
- Relapsed/Refractory Large B Cell Lymphoma
- ALLO-647
- +3 more
- (no location specified)
Feb 6, 2023
Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt
Not yet recruiting
- Relapsed/Refractory Waldenstrom Macroglobulinemia
- +3 more
- Brexucabtagene Autoleucel
- +2 more
- (no location specified)
Sep 8, 2022
Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Relapsed and/or Refractory Multiple Myeloma
- BMS-986453
- +2 more
-
Köln, GermanyLocal Institution - 0017
Dec 4, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the (Acalabrutinib (Arm A), Acalabrutinib (Arm B))
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib (Arm A)
- Acalabrutinib (Arm B)
-
Bethesda, MarylandResearch Site
Jan 3, 2023
Acute Myeloid Leukemia Trial in Beijing, Tianjin (LCAR-AMDR Cells Product)
Recruiting
- Acute Myeloid Leukemia
- LCAR-AMDR Cells Product
-
Beijing, Beijing, China
- +1 more
Jan 28, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- QH103 Cell Injection
- +2 more
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Sep 21, 2023
Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)
Not yet recruiting
- Relapsed/Refractory B-Cell Lymphoma
- FT522
- +4 more
- (no location specified)
Jul 10, 2023
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma Trial in Hackensack (Revlimid, Azacitidine)
Terminated
- Chronic Lymphocytic Leukemia(CLL)
- Small Lymphocytic Lymphoma
-
Hackensack, New JerseyHackensack University Medical Center
Jun 24, 2022
CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) Trial
Not yet recruiting
- CD5+ Relapsed/Refractory Hematopoietic Malignancies
- +5 more
- CT125A cells
- Cyclophosphamide, fludarabine
- (no location specified)
Feb 19, 2021
Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed/Refractory Large B-cell Lymphoma
- KITE-197
- +2 more
- (no location specified)
Oct 6, 2023
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma Trial (Nemtabrutinib, Venetoclax,
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +5 more
- Nemtabrutinib
- +2 more
- (no location specified)
Jul 21, 2023